Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?

Autor: Patsatsi A; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Kyriakou A; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Meltzanidou P; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Trigoni A; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Lamprou F; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Kokolios M; Autoimmune Bullous Diseases Outpatient Clinic, 2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece., Giannakou A; Laboratory of Immunology, Papageorgiou General Hospital, Thessaloniki, Greece.
Jazyk: angličtina
Zdroj: European journal of dermatology : EJD [Eur J Dermatol] 2018 Oct 01; Vol. 28 (5), pp. 711-713.
DOI: 10.1684/ejd.2018.3371
Databáze: MEDLINE
Externí odkaz: